叶下珠复方联用ADV治疗LRHB的疗效及抗病毒免疫机制的研究
|
摘要
经过多年实验研究、临床研究、反复筛选、不断优化,本研究采用叶下珠、黄芪、三七、甘草等数种中药组成了叶下珠复方,并拟将其开发为新一代的抗乙肝病毒的新药。
在进行叶下珠复方的临床研究前,我们完成体外抗乙肝病毒(HBV),对HBV转基因小鼠免疫病理模型的干预作用的实验研究,验证了其实验治疗的有效性。
在体外抗HBV的研究中,我们选择了2.2.15细胞作为体外模型,HBsAg、HBeAg作为药物效果的筛选靶标,通过MTT法测定药物的细胞毒性浓度,并相应计算出治疗指数来评价药物疗效。结果显示,叶下珠复方在2.2.15细胞中对HBsAg分泌抑制的治疗指数为8.4.因此,叶下珠复方在体外能高效、低毒的抑制HBV的分泌HbsAg和HBeAg。
叶下珠复方中、大剂量及ADV在Tg鼠血清HBsAg阴转率分别在给药后第10天、第21天、停药后3天进行比较,差异均无显著性意义,ADV具有减少HBV Tg鼠血清HBV-DNA载量的作用。但停药3天有反跳。叶下珠复方大、中剂量组均有降低HBV Tg鼠血清HBV-DNA载量的作用,尤其以大剂量组效果明显,虽然没有减少到ADV组水平,但治疗前后差异有显著性意义,且在停药后无明显反跳现象,说明叶下珠复方作用持久、平稳。模型组Tg鼠肝脏病理改变类似于临床轻度肝炎表现,随着叶下珠复方剂量的增大,炎症得以缓解。大剂量组的肝板排列整齐,无纤维组织增生,但中央静脉周围轻度围管浸润。叶下珠复方中、大剂量和ADV均能减少肝组织中HbcAg表达,尤其大剂量组明显。叶下珠复方能够上调CD3+、CD4+、CD4+/CD8+,下调CD8+T细胞比值水平,具有正向T淋巴细胞免疫调节作用,尤其以大剂量组效果明显。ADV也具有提高HBV转基因小鼠细胞免疫功能(如CD3+百分比),但作用相对叶下珠复方弱。运用大、中、小剂量叶下珠复方和ADV均能提高HBV转基因小鼠血清IL-2、TNF-γ含量,与模型组相比有显著的差异。且运用大、中剂量叶下珠复方治疗后IL-2、TNF-Y水平已高于正常对照组。叶下珠中剂量组CD3+、TNF-γ与给药前后HBV-DNA载量的减少呈显著正相关,叶下珠复方大剂量组CD4+、CD8+、CD4+/CD8+的变化与给药前后HBV-DNA减少呈显著正相关。
叶下珠复方联合阿德福韦酯(ADV)治疗拉米夫定耐药肝炎(LRHB)52周,ALT复常率、HBV-DNA阴转率、HBeAg阴转率均显著优于单纯使用ADV组,且差异显著(P<0.05或P<0.01)。治疗52周,叶下珠复方联用ADV完全应答率(CR)为25%,显著高于ADV组(10%),X2=9.07,P<0.01。叶下珠复方联合ADV组治疗52周,患者CD4+百分比和NK细胞均增加,CD3+百分比增加,而两组CD8+百分比减少,并与HBV-DNA载量的减少呈显著正相关。HBV特异型CD8+T细胞用于破坏感染肝细胞,能清除肝内HBV、从而减少细胞内HBV数目,说明叶下珠复方联合ADV能更好改善LRHB患者T淋巴细胞亚群的异常及提高NK细胞的活性,提高抗病毒的疗效。同时能调节免疫功能,使免疫低下或免疫紊乱的调整到正常,显示出较好的抗HBV效果。
For many years of experiment and clinical research, repeatedly selection and continuous optimization, our study use Phyliathu urinaria Linn (PUL), Astragalus membranaceus, pseudo-ginseng, liquorice, etc.to compose the capsule of Phyliathus Complex (PC).We hope to explore a new generation of traditional Chinese herbal combination to treat chronic hepatitis B.
Before the clinic study, we have accomplished a series of experiment research of anti-HBV in vitro,and an experiment research about the intervention of HBV transgenic mouse immunopathogenesis model.We proved the efficiency of treatment.
In the research of anti-HBV in vitro,we choose2.2.15cell as a vitro model,HBsAg、 HbeAg as drug effect of the preliminary screening targets.Though MTT method measure cell toxicity concentration of medicine,and calculate therapeutic index to evaluate medicine efficiency. Results show that, the therapeutic index of Phyliathus Complex inhibiting HBsAg in2.2.15cell is8.4.So Phyliathus Complex has high-efficiency and low-toxin to inhibit HBsAg and HBeAg in vitro.
The rate of HBsAg negative-inverted with using Phyliathus Complex of medium-dose, high-dose and ADV in Tg mouse are compared respectively at10d,21d, after without drug3d. There is no significant difference.ADV has an effect of reducing serum HBV-DNA load in HBV Tg mouse.But after without drug3d, it has a bounce.Phyliathus Complex of medium-dose, high-dose has an effect of reducing serum HBV-DNA load in HBV Tg mouse. Specially, high-dose has a significant effect. HBV-DNA load can't reduce to the level of ADV group, but there is a significant difference before and after treatment, and don't appear bounce after without drug. We can see that Phyliathus Complex have a stable and durable effect. In model group,Tg mouse liver pathological changes is similar to the expression of clinical mild hepatitis, with increasing the dose, inflammation can be relieved. The hepatic plates of high-dose group arrange appropriately, there is no fibrous tissue hyperplasia, but perivascular inflammatory infiltrates mildly. Phyliathus Complex of medium-dose, high-dose and ADV all can decrease HBcAg expression in liver issue, especially in high-dose group.Phyliathus Complex can up regulate CD3+、CD4+、CD4+/CD8+, and down regulate level of CD8+T cell, has a positive immune regulation for T cell lymphocyte, specially in high-dose group.ADV also can improve immune function of HBV transgenosis mouse cell (such as percentage of CD3+), but the effect of ADV is lower than Phyliathus Complex.Using Phyliathus Complex of high, medium,small dose and ADV can all increase serum IL-2and TNF-r content in HBV transgenosis mouse,there is a significant difference compared with control group.And after using Phyliathus Complex of high-dose and medium-dose, IL-2and TNF-γ content is higher than normal group.In Phyliathus Complex of medium-dose group, CD3+、TNF-γ have a positive correlation with reduction of HBV-DNA load before and after treatment.In high-dose group, changes of CD4+、CD8+、CD4+/CD8+have a positive correlation with reduction of HBV-DNA load before and after treatment.
Phyliathus Complex combining with ADV treat Lamivudine resistant hepatitis B (LRHB) for52weeks.ALT recovery rate, the rate of HBV-DNA and HBeAg negative-inverted are all higher than single AVD group, and there is a significant difference (P<0.05or P<0.01).After52weeks treatment, the complete response rate of Phyliathus Complex combining with ADV is25%,remarkable higher than ADV group(10%), X2=9.07,P<0.01.Using Phyliathus Complex combining with ADV group after52weeks treatment, CD4+, CD3+percentage and NK cell of patients all increase, but CD8+percentage of two group all decrease, and has a positive correlation with reduction of HBV-DNA load. HBV specific type CDg+T cells destroy infective liver cell, eliminate HBV in liver, thus reduce amount of HBV in cells.It shows, Phyliathus Complex combining with ADV can improve abnormal situation of T cell lymphocyte in LRHB patients, and increase NK cell activity, enhance antiviral efficiency. Meanwhile, Phyliathus Complex combining with ADV also can regulate immune function; make low or abnormal immune to normal situation,so it shows a better anti-HBV effect.
在进行叶下珠复方的临床研究前,我们完成体外抗乙肝病毒(HBV),对HBV转基因小鼠免疫病理模型的干预作用的实验研究,验证了其实验治疗的有效性。
在体外抗HBV的研究中,我们选择了2.2.15细胞作为体外模型,HBsAg、HBeAg作为药物效果的筛选靶标,通过MTT法测定药物的细胞毒性浓度,并相应计算出治疗指数来评价药物疗效。结果显示,叶下珠复方在2.2.15细胞中对HBsAg分泌抑制的治疗指数为8.4.因此,叶下珠复方在体外能高效、低毒的抑制HBV的分泌HbsAg和HBeAg。
叶下珠复方中、大剂量及ADV在Tg鼠血清HBsAg阴转率分别在给药后第10天、第21天、停药后3天进行比较,差异均无显著性意义,ADV具有减少HBV Tg鼠血清HBV-DNA载量的作用。但停药3天有反跳。叶下珠复方大、中剂量组均有降低HBV Tg鼠血清HBV-DNA载量的作用,尤其以大剂量组效果明显,虽然没有减少到ADV组水平,但治疗前后差异有显著性意义,且在停药后无明显反跳现象,说明叶下珠复方作用持久、平稳。模型组Tg鼠肝脏病理改变类似于临床轻度肝炎表现,随着叶下珠复方剂量的增大,炎症得以缓解。大剂量组的肝板排列整齐,无纤维组织增生,但中央静脉周围轻度围管浸润。叶下珠复方中、大剂量和ADV均能减少肝组织中HbcAg表达,尤其大剂量组明显。叶下珠复方能够上调CD3+、CD4+、CD4+/CD8+,下调CD8+T细胞比值水平,具有正向T淋巴细胞免疫调节作用,尤其以大剂量组效果明显。ADV也具有提高HBV转基因小鼠细胞免疫功能(如CD3+百分比),但作用相对叶下珠复方弱。运用大、中、小剂量叶下珠复方和ADV均能提高HBV转基因小鼠血清IL-2、TNF-γ含量,与模型组相比有显著的差异。且运用大、中剂量叶下珠复方治疗后IL-2、TNF-Y水平已高于正常对照组。叶下珠中剂量组CD3+、TNF-γ与给药前后HBV-DNA载量的减少呈显著正相关,叶下珠复方大剂量组CD4+、CD8+、CD4+/CD8+的变化与给药前后HBV-DNA减少呈显著正相关。
叶下珠复方联合阿德福韦酯(ADV)治疗拉米夫定耐药肝炎(LRHB)52周,ALT复常率、HBV-DNA阴转率、HBeAg阴转率均显著优于单纯使用ADV组,且差异显著(P<0.05或P<0.01)。治疗52周,叶下珠复方联用ADV完全应答率(CR)为25%,显著高于ADV组(10%),X2=9.07,P<0.01。叶下珠复方联合ADV组治疗52周,患者CD4+百分比和NK细胞均增加,CD3+百分比增加,而两组CD8+百分比减少,并与HBV-DNA载量的减少呈显著正相关。HBV特异型CD8+T细胞用于破坏感染肝细胞,能清除肝内HBV、从而减少细胞内HBV数目,说明叶下珠复方联合ADV能更好改善LRHB患者T淋巴细胞亚群的异常及提高NK细胞的活性,提高抗病毒的疗效。同时能调节免疫功能,使免疫低下或免疫紊乱的调整到正常,显示出较好的抗HBV效果。
For many years of experiment and clinical research, repeatedly selection and continuous optimization, our study use Phyliathu urinaria Linn (PUL), Astragalus membranaceus, pseudo-ginseng, liquorice, etc.to compose the capsule of Phyliathus Complex (PC).We hope to explore a new generation of traditional Chinese herbal combination to treat chronic hepatitis B.
Before the clinic study, we have accomplished a series of experiment research of anti-HBV in vitro,and an experiment research about the intervention of HBV transgenic mouse immunopathogenesis model.We proved the efficiency of treatment.
In the research of anti-HBV in vitro,we choose2.2.15cell as a vitro model,HBsAg、 HbeAg as drug effect of the preliminary screening targets.Though MTT method measure cell toxicity concentration of medicine,and calculate therapeutic index to evaluate medicine efficiency. Results show that, the therapeutic index of Phyliathus Complex inhibiting HBsAg in2.2.15cell is8.4.So Phyliathus Complex has high-efficiency and low-toxin to inhibit HBsAg and HBeAg in vitro.
The rate of HBsAg negative-inverted with using Phyliathus Complex of medium-dose, high-dose and ADV in Tg mouse are compared respectively at10d,21d, after without drug3d. There is no significant difference.ADV has an effect of reducing serum HBV-DNA load in HBV Tg mouse.But after without drug3d, it has a bounce.Phyliathus Complex of medium-dose, high-dose has an effect of reducing serum HBV-DNA load in HBV Tg mouse. Specially, high-dose has a significant effect. HBV-DNA load can't reduce to the level of ADV group, but there is a significant difference before and after treatment, and don't appear bounce after without drug. We can see that Phyliathus Complex have a stable and durable effect. In model group,Tg mouse liver pathological changes is similar to the expression of clinical mild hepatitis, with increasing the dose, inflammation can be relieved. The hepatic plates of high-dose group arrange appropriately, there is no fibrous tissue hyperplasia, but perivascular inflammatory infiltrates mildly. Phyliathus Complex of medium-dose, high-dose and ADV all can decrease HBcAg expression in liver issue, especially in high-dose group.Phyliathus Complex can up regulate CD3+、CD4+、CD4+/CD8+, and down regulate level of CD8+T cell, has a positive immune regulation for T cell lymphocyte, specially in high-dose group.ADV also can improve immune function of HBV transgenosis mouse cell (such as percentage of CD3+), but the effect of ADV is lower than Phyliathus Complex.Using Phyliathus Complex of high, medium,small dose and ADV can all increase serum IL-2and TNF-r content in HBV transgenosis mouse,there is a significant difference compared with control group.And after using Phyliathus Complex of high-dose and medium-dose, IL-2and TNF-γ content is higher than normal group.In Phyliathus Complex of medium-dose group, CD3+、TNF-γ have a positive correlation with reduction of HBV-DNA load before and after treatment.In high-dose group, changes of CD4+、CD8+、CD4+/CD8+have a positive correlation with reduction of HBV-DNA load before and after treatment.
Phyliathus Complex combining with ADV treat Lamivudine resistant hepatitis B (LRHB) for52weeks.ALT recovery rate, the rate of HBV-DNA and HBeAg negative-inverted are all higher than single AVD group, and there is a significant difference (P<0.05or P<0.01).After52weeks treatment, the complete response rate of Phyliathus Complex combining with ADV is25%,remarkable higher than ADV group(10%), X2=9.07,P<0.01.Using Phyliathus Complex combining with ADV group after52weeks treatment, CD4+, CD3+percentage and NK cell of patients all increase, but CD8+percentage of two group all decrease, and has a positive correlation with reduction of HBV-DNA load. HBV specific type CDg+T cells destroy infective liver cell, eliminate HBV in liver, thus reduce amount of HBV in cells.It shows, Phyliathus Complex combining with ADV can improve abnormal situation of T cell lymphocyte in LRHB patients, and increase NK cell activity, enhance antiviral efficiency. Meanwhile, Phyliathus Complex combining with ADV also can regulate immune function; make low or abnormal immune to normal situation,so it shows a better anti-HBV effect.
引文
[1]吴孟操,李梦东主编实用肝病学[M].北京：人民卫生出版社.2011.12.
[2]王灵台.中西医治疗慢性乙型肝炎的问题和对策[J].中国中西医结合杂志.2009.29(7)：583.
[3]赵庆华,李艳.从脾论治乙型病毒性肝炎[J].光明中医,2007,22(4)：21-21.
[4]康俊杰,康素琼.肝脏七病诊断和治疗[M].厦门：鹭江出版社,1994：44.
[5]高月球,陈健杰,王灵台.从毒邪论治慢性乙型肝炎的理论探讨和临床应用[J].上海中医药杂志,2006,40(3)：8-9.
[6]邱冰峰.从“伏邪”理论探讨慢性传染性疾病的治疗[J].中医研究.2005,19(9)：1-2
[7]孔祥廉,林慧,盖丽丽,梅全喜.中医药治疗病毒性肝炎研究进展[J].时珍国医国药,2009,20(3)：615-617.
[8]陈亮.补肾健脾驱邪方治疗慢性乙型肝炎32例[J].中国中医药现代远程教育.2010.8(12)：222-223.
[9]杨丽莎,乙型肝炎病毒感染不同免疫状态证候的研究思路[J].中国药物与临床,2008,8(9)：682-683.
[10]金龙飞,冯晓红,金呈之,吴腊梅,抗乙肝病毒中草药的化学成分[J].中南民族大学学报：自然科学版,2009,28(4)：59.
[11]但菊开,朱惠.中药治疗病毒性乙型肝炎的研究进展[J].时珍国医国药,2008,19[9]：2294-2295.
[12]王少丽,姚乃礼,吕文良.中药治疗慢性乙型肝炎疗效优势的研究进展[J].中国中药杂志,200732(23)：2468-2469.
[13]张金章,李森,明疏节.恩替卡韦联合中药舒肝汤治疗失代偿期肝硬化近期疗效观察[C].第二十一届全国中西医结合学会消化系统疾病学术会议.2009：388-391.
[14]于洪涛,吴剑华,康俊杰,章亭,张如棉.康氏系列方联合α-2b干扰素对慢性乙肝疗效及副作用的影响[J].湖北中医杂志,2010,32(4)：20-21.
[15]黄权祥,莫秋柏.自拟祛风保肝汤联合阿德福韦酯片治疗慢性乙型肝炎临床观察[J].辽宁中医药大学学报,2010,21(3)：126-127.
[16]杨菊,傅茂英,顾雪峰.慢性乙型肝炎湿热瘀毒症中西医结合治疗的临床及机制研究[J].现代中西医结合杂志,2010,19(7)：792-793,795.
[17]朱清静,杨玲,盛国光.慢性乙型肝炎病毒前C区基因突变与中医证型的关系[J].中国中西医结合脾胃杂志。1999,7(2)：87-88.
[18]李翰旻,赵映莉,向楠,明安萍,杨帆,陈雨,吴寿善.HBV前C区基因变异与中医证候的相关性研究[J].临床肝胆病杂志.2006,22(2)：84-85.
[19]张玮,王奕,贺德昌,李莹,邢练军,张波.HBV-YMDD变异患者与中医虚实辨证关系初探[J].辽宁中医杂志。2004.31(9)：731-732.
[20]李晓良,杨大国,邓欣,吴其恺,张云城,聂广.核苷酸耐药的慢性乙型肝炎临床特点及中医证候分析[J].新中医.2008,40(12)：32-33.
[21]苏昌田,刘毅。抗病毒治疗失败的慢性乙型肝炎管理与治疗思维[C].中华中医药学会第十三届内科肝胆病学术会议,2008.
[22]徐春华.益气凉血解毒类中药对拉米夫定诱发乙肝病毒YMDD变异的干预作用[J]。中华中医药杂志。2008.23(12)：1079-1080.
[23]陈泽雄,张涛军,胡洪涛。中药预防慢性乙型肝炎YMDD变异的临床观察[J].中西医结合肝病杂志,2005,15(3)：168-170.
[24]王泉.中西医结合治疗慢性乙型肝炎HBV-YMDD变异的临床研究[J].现代医药卫生,2007,23(2)：244-245.
[25]俞建平。复方甘草酸苷联合单磷酸阿糖腺苷对YMDD变异慢性乙型肝炎患者疗效观察[J]。中国现代应用药学杂志,2006,23(7)：701-703.
[26]杨菊,方泰惠,王志英.化肝解毒汤对慢性乙肝模型大鼠-氧化氮合酶的影响[J].中医学报.2010,25(3)：479.
[27]杨丽莎.HBV携带亚健康状态的临床意义[J].四川中医.2006,24(5)：8-10.
[28]黄峰,刘凤莉,常占杰,李响,解新科,郝明侠,张广玉.加味寿胎丸抗乙肝病毒免疫耐受的临床研究[J].陕西中医.2006,27(1)：5-6.
[29]刘瑛,吴平.扶阳活血法治疗HBV携带者42例临床观察[J].中医药导报.2007,13(6) ： 15-16.
[30]杜秀萍,陈建杰.治疗慢性乙型肝炎经验[J].河南中医,2009,29(9)855-856.
[31]方雷.叶下珠属植物化学和药理研究概况.国外医药植物药分册.1992.7(6)249-255.
[32]Thyagarajan SP. Lancet.1988.1:764-766.
[33]张绪清.苦味叶下珠的治疗作用.国外医药植物药分册.1992,7(3)：99-101.
[34]张美义.中国中药杂志,1992,17(5)：259-260.
[35]Parpaisri Petchnaree et al.Chenn Soc Perkin Jrans 1986,1:1551.
[36]Bikram singh et al.Indian Journal of Chemistry 25B 1986:600-602.
[37]Mimel shimizu et al.Chem Pharm Bull.1989,37(a):2531-2532.
[38]P satyanarayana et al,Journal of Natural Products1988,51(1):44-49.
[39]Bran etal.J. Med Biol.1984,17 (3/4).
[40]Syamasunda KV. j Ethnopharmacol.1985;14:41-49.
[41]吉力译.国外医学中医中药分册.1991,13(5)：48
[42]Venkateswaran PS, Proc Natl Acad Sci USA 1987,84:274-278
[43]Guo JT et al.The International Symposium on Research of Antiviral Drugs, P:45 1992,beijing.
[44]Mi ZB et al.The International Symposium on Research of Antiviral Drugs,P:46 1992,beijing.
[45]Blumberg BS. Vacccine.1990.8:S86-S92.
[46]Thyagara. Lancet.1990,336:949-950.
[47]Leelarlarsamce A. Lancet,1990,336:1600-1601.
[48]Brook MG. Lancet,1988,I:1017-1018.
[49]周杰。新中医.1991.22(19):470.
[50]万年松.中西医结合肝病杂志,1991；3：38
[51]Niu JZ Med Virol.1990;32(4):212-218.
[52]Wang MX. Hepatitis Scientific Memoranda.1991;2:22
[53]Wang MX Hepatitis Scientific Memoranda.1991;2:23
[54]任进余,李彩东等.苦味叶下珠治疗病毒性肝炎的研究进展.国外医学中医中药分册.1995,17(2)：11-15.
[55]彭文伟.传染病医学.第5版.北京：人民卫生出版社,2002：42.
[56]Main J, Mecarron B, Thomas HC. Treatment of chronic viral hepatitis. Antivir chem chemother.1998;9(6):449.
[57]陆伟伦.传染病学临床专论.广州：广东高等教育出版社.2000：68.
[58]Jseckel E, Manns MP. Experience with lamivudine against hepatitis B Virus, Intevirology.1997,4(5-6):322.
[59]Bruch HR,Hobner U,Mulleer R.Hepatitis B and C:current,S chuiz Rundsch Med Prar.1998;87(42):1408.
[60]Angus PW.Review:hepatitis B and liver transplantin.J Gastrenternt Hepatal.1997;12(3):217.
[61]Banic, Bertoletti A, Penne A, et al. Lamivudine treatment can restorre T cell responsiveness in chrnic hepatitis B. J chin Inevrt 1998;102(5):968.
[62]Perry CM, Faulds D.Lamivudine:A review of its antiviral activity, Pharmackinetic properties and therapeuic efficacy in the management of HIV infeetin, Drugs.1997;53(4):657.
[63]马红,尤红,尹珊等.拉米夫定治疗慢性乙型肝炎2年临床疗效.中华实验和临床病毒学杂志.2001；15：147-149.
[64]计焱焱,杨敏燕,钱又宏,等.拉米夫定治疗慢性乙型肝炎2年临床疗效及病毒的变异.肝脏,2000；5：75-77.
[65]Liaw YF, Leung NW, Chang TT, GuanR, Tai DI, NG KY, chien RN, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine study Group. Gastroenterology.2000;119:172-180.
[66]Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B eantigen seroconversion rates:results after 3years of therapy;Hepatology.2001;33:1527-1532.
[67]Mason WS;Wilson T;Innaime S,et al. Lamivudine therapy of WHV-inlectes woodchucks. Virology.1998;245(1):18.
[68]Yamanaka G;Wilson T,Innamine S,et al. etaolic studies on HMS-200475,a new antiviralcompound active against hepatitis B virus. Antimivrob Agents Chenraother.1996;43(1):190.
[69]Rajagopalan P, Boudinot FD, Chu CK, et al.Phamacokinetics of (-)-2'-3'-dideoxy-3'thiacytidine inwoodchucks.Antionicrob Agents Chemather.1996;40(3):642.
[70]Yuan GL, Morris DM, Mydlow PK, et al. Phamacokinetics, absolute bioaviliability, and absorption characteristics of lamivudine J Clin Pharmacol.1995;35(12):1174.
[71]Hands K, Inoue K, Sekiyamy K, et al.Successful treatment of an HB carrier developing severe hepatitis using lamivudine---case report. Nippan Shodakiby Gakkai Zasshi.1998;95(10):1136.
[72]Lai CL, Cling CK, Tung AKM, et al.Lamivudine is effective in suppressing hepatitis B virus DNA in chinese.Hepatitis B surface aneigen carrier:a placebo-controlled trial.Hepatology.1997;25(1):242.
[73]Sokal EM, Robert EA, Meile-Vergani G, et al.Dose-finding and safety of lamivudine(LAM) in children and adolescents with chronic hepatitis B Hepatolody.1998;(4)Part2:489A.
[74]Kocak N, Saltik IN, Ozen H, et al.Lamivudine treatment for children with interferon refactory chronic hepatitis B.Hepatology,2000,31:545.
[75]周敏,张学武,胡国启.拉米夫定治疗小儿与成人慢性乙型肝炎1年对照观察.临床荟萃.2001：16(12)：534.
[76]Sokal EM, Bortolotti F. Update on povention and treatment of viral hepatitis in children.Curr Ooin Pediatr.1999;11(5):384.
[77]Dienstag JL, Schiff ER, Mitchell M, et al.Extended lamivudine retreatment for chronic hepatitis B.Hepatology.1996;24(1):188A.
[78]Lai CL, Chien RN, Leung NW, et al.Extended lamivudine retreatment for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.N Engl J Med.1998:339(2):61.
[79]Honkoop P, de-Man RA, Niesters HG, et al.Quantitative hepatitis B verus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients:evidence of continuing viral suppression with longer duration and higher dase of lamivudine therapy.J Viral Heput.1998;5(5)307.
[80]姚光弼,王宝恩,崔振宁,等.拉米夫定治疗慢性乙型肝炎患者的长期疗效.中华肝脏病杂志.1999；7(2)：80.
[81]王磊,闫杰,李晓迎,等.拉米夫定治疗中乙肝病毒聚合酶YMDD变异的早期预测因子研究.山东医科大学学报.2002；40(1)：29-30,33.
[82]丁虹,曹宝森,裴浩.拉米夫定泛昔洛韦联合治疗慢乙肝对临床疗效的影响.临床肝胆病杂志.2002；18(6)：332-333.
[83]张晓红,杨绍基,梅咏予,等.拉米夫定联合山豆根注射液对慢性重度乙型肝炎患者抗病毒的疗效观察.中国中西医结合杂志。2002；22(9)：701-702.
[84]林炳亮,黄桂梅,张晓红,等.拉米夫定与胸腺肽α1治疗慢性乙型肝炎疗效研究.实用医学杂志.2002；18(4)：372-373.
[85]黄加权,李小丹,张泽波,等.氧化苦参碱联合拉米夫定治疗慢性乙型肝炎.医药导报.2003；22(4)：233-234.
[86]骆抗先.乙型肝炎-基础与临床.北京：人民卫生出版社,1997：345.
[87]刘亚梅叶下珠复方联合拉米夫定耐药性肝炎抗病毒免疫机制的研究.浙江中医杂志.2009；12(44)：12.
[88]张建军,施文娟,王惠芬.特异性主动免疫疗法联合拉米夫定治疗慢性乙型肝炎的临床观察.传染病信息.2002；15(3)：139.
[89]Hubert Gwn, Pieter N, et al.J Infection Dis,1998;177:1382-1385.
[90]Mazur W, Kr F, et al. Med Sci Monit.2002;8(4):CR257-262.
[91]Xing X,Hores L, Yong M, et al. Hepatology.1998;28(6:)1669.
[92]Jardi R, Bufi M, et al.Jvirol Methods.1999:83(1-2):181-187.
[93]Allen MI, Peslauriers M, Andrews CW,et al. Hepatology1998;127:1670-1677
[94]Ono Nita SK, Kato W, Shiratori Y, et al. Hepatology.1999;29(3):939-945.
[95]Yeh Ct,Chien RW, Chu CM, et al.Hepatology.2000;31(6):1318-1326.
[96]于乐成,顾长海.乙型肝炎病毒变异及其临床肝病的关系.世界华人消化杂志1999：7：978-979.
[97]马秀云,蔡浩东,崔振宇.拉米夫定相关性HBV变异对乙型肝炎预后的影响.肝脏2000：5：77-79.
[98]张欣欣,韩永年,陆志懞等.乙型肝炎病毒多聚酶变异与拉米夫定治疗反应.中华传染病杂志.2001；5：15-18.
[99]Lai CL, Yuen MF, Cheng CC. An open comperative study of lamivudine ang famiciclovir in the treatment of chronic hepatitis B.Hepatology.1998;28:318.
[100]Kobayashi S,Ide T,Sata T.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B carriers.J HePatol.2001; 34:584-586.
[101]叶晓光,王若伦,郭海波.慢性乙型肝炎患者治疗前YMDD变异基因的检测及分析.中华检验医学杂志.2002；25(4)：248.
[102]朱玫,姚光弼,钱又宏.慢性乙型肝炎病人出现YNDD变异后继续长期应用拉米夫定的疗效.Chinese Hepatology.2002;7(2):82-83,86.
[103]梁伟峰,杨丹红,沈月红,等.拉米夫定抗乙型肝炎病毒感染中YMDD变异类型及时间研究.中华肝脏病杂志.2003；11(5)：302-304.
[104]陈然峰,陈国军,董长林,等.拉米夫定抗HBV治疗过程中HBV-DNA的反弹规律及变异研究.中国实验诊断学.2002；6(6)：377-379.
[105]周永立,周耀东,田碧文.乙型肝炎病毒对拉米夫定耐药的临床研究.现代医药卫生.临床肝胆病杂志.2002；18(4)：245-246.
[106]张秀珍,张景遥,赵秀华,等.拉米夫定治疗慢乙肝的长期疗效及安全性评价.临床肝胆病杂志.2002；18(4)：245-246.
[107]姚光弼,杨敏燕,计焱焱,等.拉米夫定治疗乙型肝炎时其病毒发生YMDD变异的临床影响及处理.Chinese Hepatology.肝脏.1999：4(4)：194-196.
[108]曾民德,茅益民,姚光弼,等.阿德福韦酯治疗HBeAg阳性的中国慢性乙肝病毒性肝炎患者52周的多中心临床研究.中华传染病学杂志.2005,23：387-394.
[109]Marcellin P, Chang TT, Lim DG, et al. Adefovir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B.N Engl Med,2003,348:808-816.
[110]Marcellin P, Chang TT, Lim SG,et al. Long-term offciacy and safety of adefovir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B. hepatology,2008,48:750-758.
[111]Hadziyannis SJ, Tassopoulos NC, Heathcote,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology,2006,131:1743-1751.
[112]Hadziyannis SJ, Tassopoulos NC, Heathcote, et al. Long-term therapy with adefovir dipivoxil for HeAg-negative chronic hepatitis B,N Engl J Med.2005,352:2673-2681.
[113]Hadziyannis SJ, Tassopoulos NC, Heathcote, et al. Adefovir dipivoxil for the treatment of hepatitis B eantign-negative chronic hepatitis B. N Engl J Med.2003,348:800-807.
[114]Lamivudine P, Vigano M, Maneuti E, et al. Low resistance to adefovir combined with lamivudine:a 3-year study of 145 Lamivudine-resistant b patients. Gastrenterogy,2007,133:1445-1451.
[115]周先珊,万谟彬,郑瑞英.阿德福韦酯单药或联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究.解放军医学杂志.2009,34(2)
[116]王宇明,陈耀凯,张大志等.阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床研究.中华肝脏病杂志.2006,14(11)
[117]曾民德,茅益民,姚光弼.中华传染病杂志。2005,23(6)
[118]Rapti I, Dimon E, Mitsoula P, et al. Adding-onversus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.Hepatology.2007,45;307-313.
[119]Lamprtico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypie resistance to lamivudine. Hepatology,2005,42:1414-1419.
[120]Peters MG, Hann HH,Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic B. Gastroenterology.2004,126:91-101.
[121]Perrilllo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YNDD mutant hepatitis B Virus. Gastroenterology,2004,126:81-90.
[122]Marzzano A, Lamperticop P, Mazzaferro V, et al.Prophylaxis of hepatitis B virus recurrence after liver tramsplantation in carriers of lamivudine-resistant mutants. Liver Transpl,2005,11:532-538.
[123]张雅敏,朱志军,郑虹,等。阿德福韦酯在预防肝移植后乙肝复发中的作用.中华肝胆外科杂志,2006,12：313-315.
[124]赵鸿,张跃新,陈新月.国产阿德福韦酯片治疗拉米夫定失效HBeAg阳性慢性乙型肝炎患者的临床研究.中华内科杂志.2007,46(4)华肝胆外科杂志,2006,12：313-315.
[125]Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitisB, N Engl J Med,2006:1001-1010.
[126]Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med,2006;354:1011-1020
[127]Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology,2007, 1437-1444
[128]Yokosuka 0, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-native Japanese patients with chronic hepatitis B infection,J Hepatol,2010,52:791-799.
[129]Sherman M, Yudaydin C, Sollano J, et al.Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology, 2006,130:2039-2049.
[130]姚光弼,计焱焱,任红等.恩替卡韦治疗拉米夫定失效慢性乙型肝炎一年的疗效.中华内科杂志.2006,24：385-389
[131]姚光弼,朱玫,王宇明,等.恩替卡韦与拉米夫定治疗慢性乙型肝炎随机双盲拟对照研究.中华内科杂志.2006,45：891-895.
[132]Liaw YF, Game E, Leung N, et al.2-year GLOBE trial results:telbivudine is superior to lamivudine in patients with hepatitis B. Gastroenterology, 2009,136:486-495.
[133]Lai Cl, Gane E,Liaw YF,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med,2007,357:2576-2588.
[134]Hou J,Yin YK, Xu D, et al. Telbivudine versus lamivudine in chronic hepatitis patients with chronic hepatitis B:Results at 1 year of a randomized,double-blind trial. Hepatology,200847:447-454.
[135]Zeuzem S, Gane E, Liaw YF, et al.Baseline characteristies and early on-treatment response predict the outcomes of 2 years of telbivudine treament of chronic hepatitis B. J Hepatol,2009,51:11-20.
[136]贾继东,候金林,尹有宽,等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨.中华肝脏病杂志.2007,15：342-345.
[137]Marcellin P, Heathcote EJ, ButiM, et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic B. N Engl J Med.2008,359:2442-2445.
[138]Heathcote EJ, Marcellin P, Butim, et al. Three-year efficacy and safety of tenofovir disoproxil fumate treatment for chronic hepatitis B. Gastroenterology,2010 Oct 16. [Epub ahead of print]
[139]Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007,46;1695-1703.
[140]Keeffe EB,Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroentrol Hepatol,2007,5:890-897.
[141]胡洁.Thl/Th2免疫应答与疾病.福建医学杂志.2000(3)：118-120.
[142]李伟.慢性乙型肝炎抗病毒治疗之我见.传染病信息.2002,15(1)：5-6.
[143]刘定燮,骆抗先.乙型及丙型病毒性肝炎发病机制的新设想.第一军医大学学报,2000：13-132.
[144]卢敏,张欣欣,张志檬.亚太地区慢性乙型肝炎治疗新进展.国外医学流行病学传染病学分册,2000, (2)：80-83.
[145]唐霓.乙型肝炎病毒免疫治疗研究进展.国外医学免疫学分册.2000, (3)176-178.
[146]闻玉梅.乙型肝炎病毒感染的免疫学分类；建议与应用。中华传染病杂志,1997,1： 58.
[147]张定风.重新认识乙型肝炎防治中的几个问题.中华医学杂志,1997,1：58.
[148]Huang YH, Wu JC, Tao MH, et al. DNA-based immunization produce TH;immune resposes to hepatitis delta virus in a mouse model. Hepatology,200,32(1): 109-110.
[149]Krawczski. Experimeutal immune therapy and vaccine trial in HCV infection. J Gastroenter Hepat.2000, (Suppl):110.
[150]Manns MP, Wedemeyer H.Immunology in liver diseases:from bench to bedside.J Gastroenter hepat.2000, (Suppl):111-112.
[151]Mccaughan GW. Immubology and Immunosuppressin In:0'Grady JG, lake JR and Howdle PD, comprehensive clinical hepatology. London;Mosby,2000.36,1-20.
[152]Pols, Michel ML, Bvechot C, et al.Immune thearpy of hepatitis B virus chronic infection.Hepatology,2000,31(2):548-549.
[153]Qian S. Liver immune privilege and vulnerability to chronic infection, J Gastroent Hepat,2000(Suppl):166.
[154]Chan HL, Tang JL, Tam W, et al.The efficacy of thymosin in the treatment of chronic hepatitis B virus infection;a meta-analysis.Aliment pharmacol Ther,15:1899-1905.
[155]Chien RN, Liaw YF, Chen TC, et al.Efficacy of thymesinalphal in patients with chromic hepatitis B;a randomized controlled trial. Hepatology, 1998,27:1383-1387.
[156]杨建芬,吴轰.保元汤对慢性乙型肝炎患者免疫调节作用.湖南医科大学学报,1998, (3)：352-354.
[157]崔丽安,温玉焕,张俊福,等.慢性肝炎患者中医辨证分型与外周血T淋巴细胞亚群及SIL-2R的关系.中医杂志,1998, (8)：488-489.
[158]张剑,许晓东.慢性乙肝免疫状态与中医辨证分型的关系.浙江中医杂志.1998：444.
[159]高媛,许晓东.慢性乙型肝炎免疫状态与辨证分型的关系.北京中医药大学学报,2002,25(1)：71-72.
[160]周家禄,李秀婵,李世法.复方乙肝口服液对肝损伤的保护作用及其对免疫功能的影响.中药药理与临床,2000,16(4)：34-36.
[161]于培龙,曾惜秋.归脾汤对慢性肝炎免疫调节作用的评价。牡丹江医学院学报,2001,22(2)：40-42.
[162]谭青蓝.中医的乙型肝炎证治规律的认识.中华医药卫生杂志.2004, (3)：41-42.
[163]薛霁,曹毅荣,刘丽敏,中医药治疗慢性乙型肝炎的思路浅探.新中医,2003,35(6) ： 8-9.
[164]罗日永,何钜楠.健脾补肾法治疗乙肝e抗原阳性95例临床观察.广州中医药大学学报,1996,13(3,4)：21-23.
[165]连粤,吴婉芬.治疗慢性重症肝炎的研究.中西医结合肝病杂志,1999,9(4)：12-15.
[166]温绍昌,杨恩俊,苏国缘,右归饮对慢性乙型肝炎患者外周血T淋巴细胞亚群的影响.中华传染病杂志,1999, (3)：205.
[167]何浩,张玉亮.打破乙肝病毒免疫耐受的中药对策.新中医,2000,32(10)：56.
[168]徐冰.中医药在慢性乙型肝炎治疗中的免疫调节作用.河南中医,2004,24(4)：83-85.
[169]金介望.中医治疗慢性活动性乙型肝炎的临床观察.中西医结合杂志,1985,(6)：353.
[170]李秀惠.疏肝健脾方治疗慢性乙型肝炎临床观察.北京中医,2001, (4)：7-8
[171]任豪.四逆散合五苓散加减治疗急性黄疸型肝炎20例.湖北中医,1992,14(5)：55
[172]程润泉.四逆散临床应用三则.四川中医,1986,4(8)：131.
[173]陈继明,慢性肝炎辨治一得.中医杂志.1986；27(3)：13-15.
[174]蒲青海.黄疸肝炎临证十二法.四川中医,1986,4(8)：201.
[175]胡晨霞.四逆散的药理与临床研究进展.中国中医药信息杂志,2001,8(增刊)：18.
[176]Jiang J, Zhou C, Xu Q Alleviating effects of Si-Ni-San, a traditional Chinese prescription, on experimental liver injury and its mechanisms.Biol Pharm Bull,2003,26(8):1089-1094.
[177]蒋洁云,徐强.四逆散及其各组成中药对实验性肝损伤的影响.中国天然药物,2004,2(1)：45-49.
[178]魏伟,刘家骏,刘家琴,等.白芍总甙对乙型肝炎的治疗作用及其前景.中国药理学通报.2000
[179]温树德,吕鲁,范俊珊,等.几种中药的免疫药理及其对乙肝的治疗.医学研究通讯.1997,26(8)：31.
[180]周金黄.中药药理与临床研究进展.北京：中国科学技术出版社.1992：246.
[181]常家玲,刘振兰,石秀荣.强力宁治疗慢性活动性肝炎90例临床观察.吉林医学.1993,14(5)：299.
[182]雨谷.从药理和药化探讨小柴胡汤(三).国外医学.中医中药分册,1990,12(4)： 28.
[183]陈泽雄,张诗军,罗致强,等.小柴胡汤对慢性乙肝免疫调节及症状的作用.实用中西医结合杂志,1996.9(10)：597.
[184]刘中景,柳盛,袁有斌.加味小柴胡汤抗HBV及调节免疫的临床观察.中西医结合肝病杂志.2004,14(3)：170-171.
[185]张希东,于清欣,刘中景.拉米夫定联合小柴胡汤抗HBV及调节免疫的临床观察.中西医结合肝病杂志.2004,14(3)：170-171.
[186]张喜顺.健脾补肾治疗乙肝体会.中国医药论坛.2004,2(10)：84-85.
[187]王泽荣,吴建成.中药补肾方在体外对乙肝患者外周血淋巴细胞亚群及INF-α的调节作用.苏州大学学报(医学版).2003；23(3)：304-306.
[188]周飞,王灵台,陈建龙等.拉米夫定和补肾方联合应用治疗慢性乙型肝炎的疗效及INF-α的调节作用.苏州大学学报(医学版).2003；23(3)：309-311.
[189]刘建中,乙肝病毒血清复制指标相互关系研究.湖北预防医学杂志.2002,13(1)：6-7.
[190]金东雁,中华实验和临床病毒学杂志.1992,(6)：313.
[191]冯福民,米志宝,张习坦,等.乙型肝炎病毒前S1抗原检测方法及其临床意义探讨.天津医药.1998,26(2)：74-76.
[192]周淑芬,宋佐莉.HBV前S1蛋白的检测及其临床意义探讨.中华微生物和免疫杂志.2001,21(增刊)：106-107.
[193]赵爱英,孙永祥.203分HBV无症状携带者血清中前Sl蛋白检测结果分析.中国公共卫生.2000,16(8)：740.
[194]仝文斌,张春英,管文莉,等.乙型肝炎病毒前S2抗原、抗体检测方法的改进及其应用.中华实验和临床病毒学杂志.1997,11(3)：216-219.
[195]袁汉尧,吕世静,黄日安,等.乙肝病毒标志物时间分辨荧光免疫测定与放射免疫测定的分析比较.数理医学杂志.2003,16(5)：456-457.
[196]缪晓辉,戚中田,孔宏.微量酶联杂交法定量检测HBV基因竞争PCR扩增产物[J].中华微生物和免疫学杂志.2001,121(1)：101-104.
[197]Jaidi R,Buti M, Rodeiguez-freas F, et al.The value of quantitative detection of HBV-DNA ampilified by PCR in the study of hepayitis B infection.j hepatol,1996,24:680-685.
[198]Wu J, Sullivan OE, Gerbar MA. Quantitative polymerase chain reaction for hepatitis B virus DNA.J virol methods.1994,49:331-342.
[199]Clementi M, Menzos S, Manzi A, et al. Quantitative molecular method in virology. Archives of virology,1995,140:1523-1539.
[200]Iviaco S, Norio P, Zentilin L, et al.A novel procedure for quantitative polymerase chain reaction by co-amplification of competitive templates. Gene,1992,122:3012-3020.
[201]Uredea M, Running JA, Horn T, et al. Anovel method for the rapid detection of specific nucleotide sequence in crude biological samples without blotting or radioactivity amplification for analysis of hepatitis B virus in human serum gene.197,61:253-264.
[202]Hendericks DA,Stove BJ, Hop BS, et al. Quantitat ion of HBVDNA in human serun using a branched DNA(bDNA)signal amplification assay.Am J clin Pathol.1995,104:537-546.
[203]闫玉萍,尹格平,等.肝活检组织乙肝病毒核心抗原定量检测方法的建立[J].中华检验医学杂志,2002,25(1)：23-25.
[204]闫丽,候金林,等.乙型肝炎病毒基因型S基因PCR-RFLP分型方法的建立[J].中华传染病杂志,2001,19(4)：224-228.
[205]Okamoto H, Tsuda F, Sakuga wa H, et al. Typing hepatitis B virus by homology in nucleotide sequence:comprision of surface subtype, J Gen virol,1988,69:2575-2683.
[206]Norder H,Courouce AM, Magnius lo,et al.Complete genomes phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes Virology,1994,198:489-503.
[207]孙峥嵘,郑志红等.聚合酶链反应斑点杂交技术在临床乙型肝炎病毒检测中的应用[J].中华流行病学杂志,1998,20(4)：242-243.
[208]Satos, Suzuki K, Akahane Y, et al.Hepatitis B virus strains with mutations in the core promote in patients with fulminant hepatitis, Ann Interim Med 1995,12(2):241-246.
[209]Gunther S,Ii Bc,Miska S,et al.A novel method for efficient amplification of whole hepatitis B virus genomes permit rapid functional analysis and reveals deletion mutant in immunosuppressed patients.J Virol,1995,69:5437-5444.
[210]王虹,万成松等.采用PCR微板核酸杂交-ELISA技术进行HBVDNA基因分型的研究[J].中华微生物学和免疫学杂志,2001,21(2)：234-236.
[211]Ono Y, ondo H, Sasada R, et al.The complete nucleotide sequences of the cloned hepatitis B virus DNA subtype adr and adw. Nucleic Acids Res,1983,11: 1747-1757.
[212]Seta T, Yokoouka 0, Zmazeki F, et al.Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.J Med Virol,2000;60(1):8-16.
[213]Jardi R, Buti M, Rodriguez-Frias F, et al.Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.J Virol Methods,1999:83(1-2):181-187.
[214]Whalley SA, Brown D,Teu CG, et al. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the light Cycler. J clin Microbiol,2001;39(4):1456-1459.
[215]Stuyver L, Van Geyt C, De Gendts,et al.line probe assay for monitorring durg resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol,2000;38(2):702-707.
[216]Pastinen T, Kaitio M,Lindroo S, et al.A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res,2000;10(7):1031-1042.
[217]Hei RA, De Wide GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphouylmethoxyethyl)-adenine(PMEA)on human and duck hepatitis B virus infection Antiviral Res,1993:141-153.
[218]Jutin G, Julander,Robert W, Si dwell, Johu D, Morrey. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Resarch.2002,55:27-40.
[219]郭兴伯,朱宇同,王新华等.叶下珠复方的实验和临床研究[S].加拿大国际中医药学术大会.2002：44.
[220]Chisari FV, Klopchin K, Moriyama T,et al. Molecular pathogenesis of hepatocellular carcionma in HBV transgenic mice.Cell,1989,59:1145.
[221]骆抗先.乙型肝炎的基础和临床.北京：人民卫生出版社.第一版.1997：115-131
[222]Pasquetto V, wieland S, chisari FV. Intracelluar hepatitis B virus nueleoepsids survive eytotoxie T-lymphocyte-induced apoptosis.J virol, 2000,74:9792-9796.
[223]Wang KX, Peng JI, Wang XF, et al. Detection of Tlymphocyte subsets and mIL-2R on suface of PBMC in patients with hepatitis B.world J Gastroenterol,2003,9:2017-2020.
[224]Yang PM, Du TJ, Lai MY, et al. Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of lymphocytes.AMT Gastroenterol,1998,83:948-951.
[225]Tung MC, Spengler U, Schraut W,et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol.1991,13:313-317.
[226]Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to mutiple hepatitis B virus polymerase epitopes during and acute viral hepatitis. J Exp Med.1995,181:1047-1058.
[227]骆抗生.乙型肝炎基础与临床,北京,人民卫生出版社,第2版,2001：188-189.
[228]Kozil MJ, Cytokines in viral hepatitis. Semin Liver Dis;1999,19:157-1699.
[229]Chronic hepatitis B virus infection. J Gastoenterol Hepatol.2000,15: 46-52.
[230]黄茵.慢性感染的免疫耐药形成机制.国外医学流行病学传染病学分册.2001.(2) ： 57.
[231]陈亚冈,马亦林,屠中元等.乙型慢性活动性肝炎患者外周血淋巴细胞亚群及IL-2受体表达.中华传染病杂志,1992,10(1)：48-49.
[232]Vingrhoets J, Michielsen P,Vanham G, et al.HBV-specifie lymphopro-liferative and cytokine reponses with chronic hepatitis. J Hepatol,1998, 28:8-16.
[233]万克清,阳虚,郑宣鹤.香茹多糖注射液对慢性活动性肝炎外周血T淋巴细胞亚群和IL-2受体表达作用的研究.中国免疫学杂志,1995, (5)：298.
[234]毕青,张俊福,温玉焕等.复方仙灵脾冲剂对慢性乙型肝炎Sil-2RT淋巴细胞亚群的影响.中西医结合肝病杂志,2000, (1)：14.
[235]张广业,王亚群,张玮.中医药免疫调节治疗慢性乙型病毒性肝炎研究进展.安徽中医临床杂志,2002；14(6)：518-520.
[236]黄争荣.中药复方对慢性乙型肝炎的免疫调节作用研究进展.福建中医学院学报,2003,13(1)：62-64.
[237]周春祥,徐强,曹劲松等,四逆散改善细胞免疫性肝损伤作用机理研究.中国中医基础医学杂志,2002,8(5)：47-49.
[238]Rabey AK, Mclachlan A. The biology of hepatitis B virus. Molecular biology of the hepatitis B virus.Boca Raton, FL, CRC Press;1991:1-37.
[239]Babinet C, Farza H, Morell D, et al. Specific expression of hepatitis B surface antigen(HEsAg) in transgenic mice,Science 1985,230:1160-1163.
[240]Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenice mice. Cancer Res 1990,50: 24..-3407.
[241]Chen Y, Wei H, Gao B, et al. Activation and function of hepatic NK cells in hepatitis B infection:an underinvestigated innate immmune response. J Viral Hepatitis,2005,1:34-38.
[242]U. protzer, H. Schaller. Immune Escape by Hepatitis B viruse. Virus Genes 2000,21:1/2,27-37.
[243]Guidotti L. G, Rochford R, chung I, et al. Viral clearance without Desturuction of Infected cells During Acute HBV Infection. Science 1999,284: 825-829.
[244]Penna A, Del Prete. G,Gavalli A, et al.Predominant Thepel cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute selflimited hepatitis B. Hepatology,1997,25:1022-1027.
[245]Bertoletti A, D'Elios, MM, Boni C,et al. Different cytokine Profiles of intraphaphepatic T cells in Chronic hepatitis B and hepatitis C virus infections, Gastroenterology,1997,112:193-199.
[246]Romero R, and Lavine J. E. Cytokine inhibition of the hepatitis B virus core promoter. Hepatology,1996,23:17-23.
[247]Guy B, Pascal N, Francon A, et al. Design characterization and Dreclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine,2001,19:1794.
[248]Del Giobbo,Foli A, Balarini J, et al. Immmunouiodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine(PMEA),a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res.1991,16:65-75.
[249]Cooksley H,Chokshi S, Wedemeyer H, et al.Hepatitis B virus-specific T-cell reactivity during adeforvir dipivoxil(ADV)treatment:a mulyicentre, controlled study.J Hepatol,2002,36;7.
[250]刘林华,阿德福韦酯抗乙肝病毒治疗进展.国外医学病毒学分册.2005,12(5)：154.
[251]周娟,李连闯,毕明刚等.慢性乙肝的细胞免疫病毒和中药与植物药治疗.国外医学.植物药分册,2006,21(5);202-206.
[252]顾缨.中药免疫调节剂治疗乙型病毒性肝炎的研究近况.中医药临床杂志,2005,17(3)：311-312.
[253]Bertoletti A, Maini MK. Protection or damage:a dual role for the virus-specigfic cytotoxic T lymphocyte response in hepipis B cudc infection curr Opin Immunol,2000,12:403-408.
[254]Boni C,Penna A, Ogg GS, Bertoletti A,et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy. Hepatalogy,2001,33:963-967.
[255]Fukuda R, Ishimura N, Nguyen TX, et al. The expression of and IL-2, IL-4 and interferon-gamma(INF-ganmma)mRNA/using liver different prases of acute exaceberbation if chronic hepatitis B chi clin Exp Immunol,1995,
100(3):446-451.
[256]孙剑,候金林.慢性乙型肝炎核苷类似物治疗过程中耐药性的产生及防治[J].国外医学内科分册.1998,25(10)：422.
[257]中华医学会传染病分会.肝病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2006.15-17.
[258]拉米夫定临床应用专家组.2004年拉米夫定临床应用应用专家共识.中华肝脏病杂志,2006：15-17.
[259]Locamini SA, Hepatitis B virus surface antigen and polynerase genevariant:potential virological and clinical significance[J]. Hepatology.1998,27:294.
[260]Dusheika G. Lamivudine therapy for hepatitis B infection[J]Seand J Gastroenterol,1999,230(suppl):76.
[261]刘林华,陈新月.阿德福韦酯抗乙肝病毒治疗进展[J].国外医学病毒学分册.2005,12(5)：235-237.
[2]王灵台.中西医治疗慢性乙型肝炎的问题和对策[J].中国中西医结合杂志.2009.29(7)：583.
[3]赵庆华,李艳.从脾论治乙型病毒性肝炎[J].光明中医,2007,22(4)：21-21.
[4]康俊杰,康素琼.肝脏七病诊断和治疗[M].厦门：鹭江出版社,1994：44.
[5]高月球,陈健杰,王灵台.从毒邪论治慢性乙型肝炎的理论探讨和临床应用[J].上海中医药杂志,2006,40(3)：8-9.
[6]邱冰峰.从“伏邪”理论探讨慢性传染性疾病的治疗[J].中医研究.2005,19(9)：1-2
[7]孔祥廉,林慧,盖丽丽,梅全喜.中医药治疗病毒性肝炎研究进展[J].时珍国医国药,2009,20(3)：615-617.
[8]陈亮.补肾健脾驱邪方治疗慢性乙型肝炎32例[J].中国中医药现代远程教育.2010.8(12)：222-223.
[9]杨丽莎,乙型肝炎病毒感染不同免疫状态证候的研究思路[J].中国药物与临床,2008,8(9)：682-683.
[10]金龙飞,冯晓红,金呈之,吴腊梅,抗乙肝病毒中草药的化学成分[J].中南民族大学学报：自然科学版,2009,28(4)：59.
[11]但菊开,朱惠.中药治疗病毒性乙型肝炎的研究进展[J].时珍国医国药,2008,19[9]：2294-2295.
[12]王少丽,姚乃礼,吕文良.中药治疗慢性乙型肝炎疗效优势的研究进展[J].中国中药杂志,200732(23)：2468-2469.
[13]张金章,李森,明疏节.恩替卡韦联合中药舒肝汤治疗失代偿期肝硬化近期疗效观察[C].第二十一届全国中西医结合学会消化系统疾病学术会议.2009：388-391.
[14]于洪涛,吴剑华,康俊杰,章亭,张如棉.康氏系列方联合α-2b干扰素对慢性乙肝疗效及副作用的影响[J].湖北中医杂志,2010,32(4)：20-21.
[15]黄权祥,莫秋柏.自拟祛风保肝汤联合阿德福韦酯片治疗慢性乙型肝炎临床观察[J].辽宁中医药大学学报,2010,21(3)：126-127.
[16]杨菊,傅茂英,顾雪峰.慢性乙型肝炎湿热瘀毒症中西医结合治疗的临床及机制研究[J].现代中西医结合杂志,2010,19(7)：792-793,795.
[17]朱清静,杨玲,盛国光.慢性乙型肝炎病毒前C区基因突变与中医证型的关系[J].中国中西医结合脾胃杂志。1999,7(2)：87-88.
[18]李翰旻,赵映莉,向楠,明安萍,杨帆,陈雨,吴寿善.HBV前C区基因变异与中医证候的相关性研究[J].临床肝胆病杂志.2006,22(2)：84-85.
[19]张玮,王奕,贺德昌,李莹,邢练军,张波.HBV-YMDD变异患者与中医虚实辨证关系初探[J].辽宁中医杂志。2004.31(9)：731-732.
[20]李晓良,杨大国,邓欣,吴其恺,张云城,聂广.核苷酸耐药的慢性乙型肝炎临床特点及中医证候分析[J].新中医.2008,40(12)：32-33.
[21]苏昌田,刘毅。抗病毒治疗失败的慢性乙型肝炎管理与治疗思维[C].中华中医药学会第十三届内科肝胆病学术会议,2008.
[22]徐春华.益气凉血解毒类中药对拉米夫定诱发乙肝病毒YMDD变异的干预作用[J]。中华中医药杂志。2008.23(12)：1079-1080.
[23]陈泽雄,张涛军,胡洪涛。中药预防慢性乙型肝炎YMDD变异的临床观察[J].中西医结合肝病杂志,2005,15(3)：168-170.
[24]王泉.中西医结合治疗慢性乙型肝炎HBV-YMDD变异的临床研究[J].现代医药卫生,2007,23(2)：244-245.
[25]俞建平。复方甘草酸苷联合单磷酸阿糖腺苷对YMDD变异慢性乙型肝炎患者疗效观察[J]。中国现代应用药学杂志,2006,23(7)：701-703.
[26]杨菊,方泰惠,王志英.化肝解毒汤对慢性乙肝模型大鼠-氧化氮合酶的影响[J].中医学报.2010,25(3)：479.
[27]杨丽莎.HBV携带亚健康状态的临床意义[J].四川中医.2006,24(5)：8-10.
[28]黄峰,刘凤莉,常占杰,李响,解新科,郝明侠,张广玉.加味寿胎丸抗乙肝病毒免疫耐受的临床研究[J].陕西中医.2006,27(1)：5-6.
[29]刘瑛,吴平.扶阳活血法治疗HBV携带者42例临床观察[J].中医药导报.2007,13(6) ： 15-16.
[30]杜秀萍,陈建杰.治疗慢性乙型肝炎经验[J].河南中医,2009,29(9)855-856.
[31]方雷.叶下珠属植物化学和药理研究概况.国外医药植物药分册.1992.7(6)249-255.
[32]Thyagarajan SP. Lancet.1988.1:764-766.
[33]张绪清.苦味叶下珠的治疗作用.国外医药植物药分册.1992,7(3)：99-101.
[34]张美义.中国中药杂志,1992,17(5)：259-260.
[35]Parpaisri Petchnaree et al.Chenn Soc Perkin Jrans 1986,1:1551.
[36]Bikram singh et al.Indian Journal of Chemistry 25B 1986:600-602.
[37]Mimel shimizu et al.Chem Pharm Bull.1989,37(a):2531-2532.
[38]P satyanarayana et al,Journal of Natural Products1988,51(1):44-49.
[39]Bran etal.J. Med Biol.1984,17 (3/4).
[40]Syamasunda KV. j Ethnopharmacol.1985;14:41-49.
[41]吉力译.国外医学中医中药分册.1991,13(5)：48
[42]Venkateswaran PS, Proc Natl Acad Sci USA 1987,84:274-278
[43]Guo JT et al.The International Symposium on Research of Antiviral Drugs, P:45 1992,beijing.
[44]Mi ZB et al.The International Symposium on Research of Antiviral Drugs,P:46 1992,beijing.
[45]Blumberg BS. Vacccine.1990.8:S86-S92.
[46]Thyagara. Lancet.1990,336:949-950.
[47]Leelarlarsamce A. Lancet,1990,336:1600-1601.
[48]Brook MG. Lancet,1988,I:1017-1018.
[49]周杰。新中医.1991.22(19):470.
[50]万年松.中西医结合肝病杂志,1991；3：38
[51]Niu JZ Med Virol.1990;32(4):212-218.
[52]Wang MX. Hepatitis Scientific Memoranda.1991;2:22
[53]Wang MX Hepatitis Scientific Memoranda.1991;2:23
[54]任进余,李彩东等.苦味叶下珠治疗病毒性肝炎的研究进展.国外医学中医中药分册.1995,17(2)：11-15.
[55]彭文伟.传染病医学.第5版.北京：人民卫生出版社,2002：42.
[56]Main J, Mecarron B, Thomas HC. Treatment of chronic viral hepatitis. Antivir chem chemother.1998;9(6):449.
[57]陆伟伦.传染病学临床专论.广州：广东高等教育出版社.2000：68.
[58]Jseckel E, Manns MP. Experience with lamivudine against hepatitis B Virus, Intevirology.1997,4(5-6):322.
[59]Bruch HR,Hobner U,Mulleer R.Hepatitis B and C:current,S chuiz Rundsch Med Prar.1998;87(42):1408.
[60]Angus PW.Review:hepatitis B and liver transplantin.J Gastrenternt Hepatal.1997;12(3):217.
[61]Banic, Bertoletti A, Penne A, et al. Lamivudine treatment can restorre T cell responsiveness in chrnic hepatitis B. J chin Inevrt 1998;102(5):968.
[62]Perry CM, Faulds D.Lamivudine:A review of its antiviral activity, Pharmackinetic properties and therapeuic efficacy in the management of HIV infeetin, Drugs.1997;53(4):657.
[63]马红,尤红,尹珊等.拉米夫定治疗慢性乙型肝炎2年临床疗效.中华实验和临床病毒学杂志.2001；15：147-149.
[64]计焱焱,杨敏燕,钱又宏,等.拉米夫定治疗慢性乙型肝炎2年临床疗效及病毒的变异.肝脏,2000；5：75-77.
[65]Liaw YF, Leung NW, Chang TT, GuanR, Tai DI, NG KY, chien RN, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine study Group. Gastroenterology.2000;119:172-180.
[66]Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B eantigen seroconversion rates:results after 3years of therapy;Hepatology.2001;33:1527-1532.
[67]Mason WS;Wilson T;Innaime S,et al. Lamivudine therapy of WHV-inlectes woodchucks. Virology.1998;245(1):18.
[68]Yamanaka G;Wilson T,Innamine S,et al. etaolic studies on HMS-200475,a new antiviralcompound active against hepatitis B virus. Antimivrob Agents Chenraother.1996;43(1):190.
[69]Rajagopalan P, Boudinot FD, Chu CK, et al.Phamacokinetics of (-)-2'-3'-dideoxy-3'thiacytidine inwoodchucks.Antionicrob Agents Chemather.1996;40(3):642.
[70]Yuan GL, Morris DM, Mydlow PK, et al. Phamacokinetics, absolute bioaviliability, and absorption characteristics of lamivudine J Clin Pharmacol.1995;35(12):1174.
[71]Hands K, Inoue K, Sekiyamy K, et al.Successful treatment of an HB carrier developing severe hepatitis using lamivudine---case report. Nippan Shodakiby Gakkai Zasshi.1998;95(10):1136.
[72]Lai CL, Cling CK, Tung AKM, et al.Lamivudine is effective in suppressing hepatitis B virus DNA in chinese.Hepatitis B surface aneigen carrier:a placebo-controlled trial.Hepatology.1997;25(1):242.
[73]Sokal EM, Robert EA, Meile-Vergani G, et al.Dose-finding and safety of lamivudine(LAM) in children and adolescents with chronic hepatitis B Hepatolody.1998;(4)Part2:489A.
[74]Kocak N, Saltik IN, Ozen H, et al.Lamivudine treatment for children with interferon refactory chronic hepatitis B.Hepatology,2000,31:545.
[75]周敏,张学武,胡国启.拉米夫定治疗小儿与成人慢性乙型肝炎1年对照观察.临床荟萃.2001：16(12)：534.
[76]Sokal EM, Bortolotti F. Update on povention and treatment of viral hepatitis in children.Curr Ooin Pediatr.1999;11(5):384.
[77]Dienstag JL, Schiff ER, Mitchell M, et al.Extended lamivudine retreatment for chronic hepatitis B.Hepatology.1996;24(1):188A.
[78]Lai CL, Chien RN, Leung NW, et al.Extended lamivudine retreatment for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.N Engl J Med.1998:339(2):61.
[79]Honkoop P, de-Man RA, Niesters HG, et al.Quantitative hepatitis B verus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients:evidence of continuing viral suppression with longer duration and higher dase of lamivudine therapy.J Viral Heput.1998;5(5)307.
[80]姚光弼,王宝恩,崔振宁,等.拉米夫定治疗慢性乙型肝炎患者的长期疗效.中华肝脏病杂志.1999；7(2)：80.
[81]王磊,闫杰,李晓迎,等.拉米夫定治疗中乙肝病毒聚合酶YMDD变异的早期预测因子研究.山东医科大学学报.2002；40(1)：29-30,33.
[82]丁虹,曹宝森,裴浩.拉米夫定泛昔洛韦联合治疗慢乙肝对临床疗效的影响.临床肝胆病杂志.2002；18(6)：332-333.
[83]张晓红,杨绍基,梅咏予,等.拉米夫定联合山豆根注射液对慢性重度乙型肝炎患者抗病毒的疗效观察.中国中西医结合杂志。2002；22(9)：701-702.
[84]林炳亮,黄桂梅,张晓红,等.拉米夫定与胸腺肽α1治疗慢性乙型肝炎疗效研究.实用医学杂志.2002；18(4)：372-373.
[85]黄加权,李小丹,张泽波,等.氧化苦参碱联合拉米夫定治疗慢性乙型肝炎.医药导报.2003；22(4)：233-234.
[86]骆抗先.乙型肝炎-基础与临床.北京：人民卫生出版社,1997：345.
[87]刘亚梅叶下珠复方联合拉米夫定耐药性肝炎抗病毒免疫机制的研究.浙江中医杂志.2009；12(44)：12.
[88]张建军,施文娟,王惠芬.特异性主动免疫疗法联合拉米夫定治疗慢性乙型肝炎的临床观察.传染病信息.2002；15(3)：139.
[89]Hubert Gwn, Pieter N, et al.J Infection Dis,1998;177:1382-1385.
[90]Mazur W, Kr F, et al. Med Sci Monit.2002;8(4):CR257-262.
[91]Xing X,Hores L, Yong M, et al. Hepatology.1998;28(6:)1669.
[92]Jardi R, Bufi M, et al.Jvirol Methods.1999:83(1-2):181-187.
[93]Allen MI, Peslauriers M, Andrews CW,et al. Hepatology1998;127:1670-1677
[94]Ono Nita SK, Kato W, Shiratori Y, et al. Hepatology.1999;29(3):939-945.
[95]Yeh Ct,Chien RW, Chu CM, et al.Hepatology.2000;31(6):1318-1326.
[96]于乐成,顾长海.乙型肝炎病毒变异及其临床肝病的关系.世界华人消化杂志1999：7：978-979.
[97]马秀云,蔡浩东,崔振宇.拉米夫定相关性HBV变异对乙型肝炎预后的影响.肝脏2000：5：77-79.
[98]张欣欣,韩永年,陆志懞等.乙型肝炎病毒多聚酶变异与拉米夫定治疗反应.中华传染病杂志.2001；5：15-18.
[99]Lai CL, Yuen MF, Cheng CC. An open comperative study of lamivudine ang famiciclovir in the treatment of chronic hepatitis B.Hepatology.1998;28:318.
[100]Kobayashi S,Ide T,Sata T.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B carriers.J HePatol.2001; 34:584-586.
[101]叶晓光,王若伦,郭海波.慢性乙型肝炎患者治疗前YMDD变异基因的检测及分析.中华检验医学杂志.2002；25(4)：248.
[102]朱玫,姚光弼,钱又宏.慢性乙型肝炎病人出现YNDD变异后继续长期应用拉米夫定的疗效.Chinese Hepatology.2002;7(2):82-83,86.
[103]梁伟峰,杨丹红,沈月红,等.拉米夫定抗乙型肝炎病毒感染中YMDD变异类型及时间研究.中华肝脏病杂志.2003；11(5)：302-304.
[104]陈然峰,陈国军,董长林,等.拉米夫定抗HBV治疗过程中HBV-DNA的反弹规律及变异研究.中国实验诊断学.2002；6(6)：377-379.
[105]周永立,周耀东,田碧文.乙型肝炎病毒对拉米夫定耐药的临床研究.现代医药卫生.临床肝胆病杂志.2002；18(4)：245-246.
[106]张秀珍,张景遥,赵秀华,等.拉米夫定治疗慢乙肝的长期疗效及安全性评价.临床肝胆病杂志.2002；18(4)：245-246.
[107]姚光弼,杨敏燕,计焱焱,等.拉米夫定治疗乙型肝炎时其病毒发生YMDD变异的临床影响及处理.Chinese Hepatology.肝脏.1999：4(4)：194-196.
[108]曾民德,茅益民,姚光弼,等.阿德福韦酯治疗HBeAg阳性的中国慢性乙肝病毒性肝炎患者52周的多中心临床研究.中华传染病学杂志.2005,23：387-394.
[109]Marcellin P, Chang TT, Lim DG, et al. Adefovir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B.N Engl Med,2003,348:808-816.
[110]Marcellin P, Chang TT, Lim SG,et al. Long-term offciacy and safety of adefovir dipivoxil for the treatment of hepatitis B eantigen-positive chronic hepatitis B. hepatology,2008,48:750-758.
[111]Hadziyannis SJ, Tassopoulos NC, Heathcote,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology,2006,131:1743-1751.
[112]Hadziyannis SJ, Tassopoulos NC, Heathcote, et al. Long-term therapy with adefovir dipivoxil for HeAg-negative chronic hepatitis B,N Engl J Med.2005,352:2673-2681.
[113]Hadziyannis SJ, Tassopoulos NC, Heathcote, et al. Adefovir dipivoxil for the treatment of hepatitis B eantign-negative chronic hepatitis B. N Engl J Med.2003,348:800-807.
[114]Lamivudine P, Vigano M, Maneuti E, et al. Low resistance to adefovir combined with lamivudine:a 3-year study of 145 Lamivudine-resistant b patients. Gastrenterogy,2007,133:1445-1451.
[115]周先珊,万谟彬,郑瑞英.阿德福韦酯单药或联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究.解放军医学杂志.2009,34(2)
[116]王宇明,陈耀凯,张大志等.阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床研究.中华肝脏病杂志.2006,14(11)
[117]曾民德,茅益民,姚光弼.中华传染病杂志。2005,23(6)
[118]Rapti I, Dimon E, Mitsoula P, et al. Adding-onversus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.Hepatology.2007,45;307-313.
[119]Lamprtico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypie resistance to lamivudine. Hepatology,2005,42:1414-1419.
[120]Peters MG, Hann HH,Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic B. Gastroenterology.2004,126:91-101.
[121]Perrilllo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YNDD mutant hepatitis B Virus. Gastroenterology,2004,126:81-90.
[122]Marzzano A, Lamperticop P, Mazzaferro V, et al.Prophylaxis of hepatitis B virus recurrence after liver tramsplantation in carriers of lamivudine-resistant mutants. Liver Transpl,2005,11:532-538.
[123]张雅敏,朱志军,郑虹,等。阿德福韦酯在预防肝移植后乙肝复发中的作用.中华肝胆外科杂志,2006,12：313-315.
[124]赵鸿,张跃新,陈新月.国产阿德福韦酯片治疗拉米夫定失效HBeAg阳性慢性乙型肝炎患者的临床研究.中华内科杂志.2007,46(4)华肝胆外科杂志,2006,12：313-315.
[125]Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitisB, N Engl J Med,2006:1001-1010.
[126]Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med,2006;354:1011-1020
[127]Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology,2007, 1437-1444
[128]Yokosuka 0, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-native Japanese patients with chronic hepatitis B infection,J Hepatol,2010,52:791-799.
[129]Sherman M, Yudaydin C, Sollano J, et al.Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology, 2006,130:2039-2049.
[130]姚光弼,计焱焱,任红等.恩替卡韦治疗拉米夫定失效慢性乙型肝炎一年的疗效.中华内科杂志.2006,24：385-389
[131]姚光弼,朱玫,王宇明,等.恩替卡韦与拉米夫定治疗慢性乙型肝炎随机双盲拟对照研究.中华内科杂志.2006,45：891-895.
[132]Liaw YF, Game E, Leung N, et al.2-year GLOBE trial results:telbivudine is superior to lamivudine in patients with hepatitis B. Gastroenterology, 2009,136:486-495.
[133]Lai Cl, Gane E,Liaw YF,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med,2007,357:2576-2588.
[134]Hou J,Yin YK, Xu D, et al. Telbivudine versus lamivudine in chronic hepatitis patients with chronic hepatitis B:Results at 1 year of a randomized,double-blind trial. Hepatology,200847:447-454.
[135]Zeuzem S, Gane E, Liaw YF, et al.Baseline characteristies and early on-treatment response predict the outcomes of 2 years of telbivudine treament of chronic hepatitis B. J Hepatol,2009,51:11-20.
[136]贾继东,候金林,尹有宽,等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨.中华肝脏病杂志.2007,15：342-345.
[137]Marcellin P, Heathcote EJ, ButiM, et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic B. N Engl J Med.2008,359:2442-2445.
[138]Heathcote EJ, Marcellin P, Butim, et al. Three-year efficacy and safety of tenofovir disoproxil fumate treatment for chronic hepatitis B. Gastroenterology,2010 Oct 16. [Epub ahead of print]
[139]Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007,46;1695-1703.
[140]Keeffe EB,Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroentrol Hepatol,2007,5:890-897.
[141]胡洁.Thl/Th2免疫应答与疾病.福建医学杂志.2000(3)：118-120.
[142]李伟.慢性乙型肝炎抗病毒治疗之我见.传染病信息.2002,15(1)：5-6.
[143]刘定燮,骆抗先.乙型及丙型病毒性肝炎发病机制的新设想.第一军医大学学报,2000：13-132.
[144]卢敏,张欣欣,张志檬.亚太地区慢性乙型肝炎治疗新进展.国外医学流行病学传染病学分册,2000, (2)：80-83.
[145]唐霓.乙型肝炎病毒免疫治疗研究进展.国外医学免疫学分册.2000, (3)176-178.
[146]闻玉梅.乙型肝炎病毒感染的免疫学分类；建议与应用。中华传染病杂志,1997,1： 58.
[147]张定风.重新认识乙型肝炎防治中的几个问题.中华医学杂志,1997,1：58.
[148]Huang YH, Wu JC, Tao MH, et al. DNA-based immunization produce TH;immune resposes to hepatitis delta virus in a mouse model. Hepatology,200,32(1): 109-110.
[149]Krawczski. Experimeutal immune therapy and vaccine trial in HCV infection. J Gastroenter Hepat.2000, (Suppl):110.
[150]Manns MP, Wedemeyer H.Immunology in liver diseases:from bench to bedside.J Gastroenter hepat.2000, (Suppl):111-112.
[151]Mccaughan GW. Immubology and Immunosuppressin In:0'Grady JG, lake JR and Howdle PD, comprehensive clinical hepatology. London;Mosby,2000.36,1-20.
[152]Pols, Michel ML, Bvechot C, et al.Immune thearpy of hepatitis B virus chronic infection.Hepatology,2000,31(2):548-549.
[153]Qian S. Liver immune privilege and vulnerability to chronic infection, J Gastroent Hepat,2000(Suppl):166.
[154]Chan HL, Tang JL, Tam W, et al.The efficacy of thymosin in the treatment of chronic hepatitis B virus infection;a meta-analysis.Aliment pharmacol Ther,15:1899-1905.
[155]Chien RN, Liaw YF, Chen TC, et al.Efficacy of thymesinalphal in patients with chromic hepatitis B;a randomized controlled trial. Hepatology, 1998,27:1383-1387.
[156]杨建芬,吴轰.保元汤对慢性乙型肝炎患者免疫调节作用.湖南医科大学学报,1998, (3)：352-354.
[157]崔丽安,温玉焕,张俊福,等.慢性肝炎患者中医辨证分型与外周血T淋巴细胞亚群及SIL-2R的关系.中医杂志,1998, (8)：488-489.
[158]张剑,许晓东.慢性乙肝免疫状态与中医辨证分型的关系.浙江中医杂志.1998：444.
[159]高媛,许晓东.慢性乙型肝炎免疫状态与辨证分型的关系.北京中医药大学学报,2002,25(1)：71-72.
[160]周家禄,李秀婵,李世法.复方乙肝口服液对肝损伤的保护作用及其对免疫功能的影响.中药药理与临床,2000,16(4)：34-36.
[161]于培龙,曾惜秋.归脾汤对慢性肝炎免疫调节作用的评价。牡丹江医学院学报,2001,22(2)：40-42.
[162]谭青蓝.中医的乙型肝炎证治规律的认识.中华医药卫生杂志.2004, (3)：41-42.
[163]薛霁,曹毅荣,刘丽敏,中医药治疗慢性乙型肝炎的思路浅探.新中医,2003,35(6) ： 8-9.
[164]罗日永,何钜楠.健脾补肾法治疗乙肝e抗原阳性95例临床观察.广州中医药大学学报,1996,13(3,4)：21-23.
[165]连粤,吴婉芬.治疗慢性重症肝炎的研究.中西医结合肝病杂志,1999,9(4)：12-15.
[166]温绍昌,杨恩俊,苏国缘,右归饮对慢性乙型肝炎患者外周血T淋巴细胞亚群的影响.中华传染病杂志,1999, (3)：205.
[167]何浩,张玉亮.打破乙肝病毒免疫耐受的中药对策.新中医,2000,32(10)：56.
[168]徐冰.中医药在慢性乙型肝炎治疗中的免疫调节作用.河南中医,2004,24(4)：83-85.
[169]金介望.中医治疗慢性活动性乙型肝炎的临床观察.中西医结合杂志,1985,(6)：353.
[170]李秀惠.疏肝健脾方治疗慢性乙型肝炎临床观察.北京中医,2001, (4)：7-8
[171]任豪.四逆散合五苓散加减治疗急性黄疸型肝炎20例.湖北中医,1992,14(5)：55
[172]程润泉.四逆散临床应用三则.四川中医,1986,4(8)：131.
[173]陈继明,慢性肝炎辨治一得.中医杂志.1986；27(3)：13-15.
[174]蒲青海.黄疸肝炎临证十二法.四川中医,1986,4(8)：201.
[175]胡晨霞.四逆散的药理与临床研究进展.中国中医药信息杂志,2001,8(增刊)：18.
[176]Jiang J, Zhou C, Xu Q Alleviating effects of Si-Ni-San, a traditional Chinese prescription, on experimental liver injury and its mechanisms.Biol Pharm Bull,2003,26(8):1089-1094.
[177]蒋洁云,徐强.四逆散及其各组成中药对实验性肝损伤的影响.中国天然药物,2004,2(1)：45-49.
[178]魏伟,刘家骏,刘家琴,等.白芍总甙对乙型肝炎的治疗作用及其前景.中国药理学通报.2000
[179]温树德,吕鲁,范俊珊,等.几种中药的免疫药理及其对乙肝的治疗.医学研究通讯.1997,26(8)：31.
[180]周金黄.中药药理与临床研究进展.北京：中国科学技术出版社.1992：246.
[181]常家玲,刘振兰,石秀荣.强力宁治疗慢性活动性肝炎90例临床观察.吉林医学.1993,14(5)：299.
[182]雨谷.从药理和药化探讨小柴胡汤(三).国外医学.中医中药分册,1990,12(4)： 28.
[183]陈泽雄,张诗军,罗致强,等.小柴胡汤对慢性乙肝免疫调节及症状的作用.实用中西医结合杂志,1996.9(10)：597.
[184]刘中景,柳盛,袁有斌.加味小柴胡汤抗HBV及调节免疫的临床观察.中西医结合肝病杂志.2004,14(3)：170-171.
[185]张希东,于清欣,刘中景.拉米夫定联合小柴胡汤抗HBV及调节免疫的临床观察.中西医结合肝病杂志.2004,14(3)：170-171.
[186]张喜顺.健脾补肾治疗乙肝体会.中国医药论坛.2004,2(10)：84-85.
[187]王泽荣,吴建成.中药补肾方在体外对乙肝患者外周血淋巴细胞亚群及INF-α的调节作用.苏州大学学报(医学版).2003；23(3)：304-306.
[188]周飞,王灵台,陈建龙等.拉米夫定和补肾方联合应用治疗慢性乙型肝炎的疗效及INF-α的调节作用.苏州大学学报(医学版).2003；23(3)：309-311.
[189]刘建中,乙肝病毒血清复制指标相互关系研究.湖北预防医学杂志.2002,13(1)：6-7.
[190]金东雁,中华实验和临床病毒学杂志.1992,(6)：313.
[191]冯福民,米志宝,张习坦,等.乙型肝炎病毒前S1抗原检测方法及其临床意义探讨.天津医药.1998,26(2)：74-76.
[192]周淑芬,宋佐莉.HBV前S1蛋白的检测及其临床意义探讨.中华微生物和免疫杂志.2001,21(增刊)：106-107.
[193]赵爱英,孙永祥.203分HBV无症状携带者血清中前Sl蛋白检测结果分析.中国公共卫生.2000,16(8)：740.
[194]仝文斌,张春英,管文莉,等.乙型肝炎病毒前S2抗原、抗体检测方法的改进及其应用.中华实验和临床病毒学杂志.1997,11(3)：216-219.
[195]袁汉尧,吕世静,黄日安,等.乙肝病毒标志物时间分辨荧光免疫测定与放射免疫测定的分析比较.数理医学杂志.2003,16(5)：456-457.
[196]缪晓辉,戚中田,孔宏.微量酶联杂交法定量检测HBV基因竞争PCR扩增产物[J].中华微生物和免疫学杂志.2001,121(1)：101-104.
[197]Jaidi R,Buti M, Rodeiguez-freas F, et al.The value of quantitative detection of HBV-DNA ampilified by PCR in the study of hepayitis B infection.j hepatol,1996,24:680-685.
[198]Wu J, Sullivan OE, Gerbar MA. Quantitative polymerase chain reaction for hepatitis B virus DNA.J virol methods.1994,49:331-342.
[199]Clementi M, Menzos S, Manzi A, et al. Quantitative molecular method in virology. Archives of virology,1995,140:1523-1539.
[200]Iviaco S, Norio P, Zentilin L, et al.A novel procedure for quantitative polymerase chain reaction by co-amplification of competitive templates. Gene,1992,122:3012-3020.
[201]Uredea M, Running JA, Horn T, et al. Anovel method for the rapid detection of specific nucleotide sequence in crude biological samples without blotting or radioactivity amplification for analysis of hepatitis B virus in human serum gene.197,61:253-264.
[202]Hendericks DA,Stove BJ, Hop BS, et al. Quantitat ion of HBVDNA in human serun using a branched DNA(bDNA)signal amplification assay.Am J clin Pathol.1995,104:537-546.
[203]闫玉萍,尹格平,等.肝活检组织乙肝病毒核心抗原定量检测方法的建立[J].中华检验医学杂志,2002,25(1)：23-25.
[204]闫丽,候金林,等.乙型肝炎病毒基因型S基因PCR-RFLP分型方法的建立[J].中华传染病杂志,2001,19(4)：224-228.
[205]Okamoto H, Tsuda F, Sakuga wa H, et al. Typing hepatitis B virus by homology in nucleotide sequence:comprision of surface subtype, J Gen virol,1988,69:2575-2683.
[206]Norder H,Courouce AM, Magnius lo,et al.Complete genomes phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes Virology,1994,198:489-503.
[207]孙峥嵘,郑志红等.聚合酶链反应斑点杂交技术在临床乙型肝炎病毒检测中的应用[J].中华流行病学杂志,1998,20(4)：242-243.
[208]Satos, Suzuki K, Akahane Y, et al.Hepatitis B virus strains with mutations in the core promote in patients with fulminant hepatitis, Ann Interim Med 1995,12(2):241-246.
[209]Gunther S,Ii Bc,Miska S,et al.A novel method for efficient amplification of whole hepatitis B virus genomes permit rapid functional analysis and reveals deletion mutant in immunosuppressed patients.J Virol,1995,69:5437-5444.
[210]王虹,万成松等.采用PCR微板核酸杂交-ELISA技术进行HBVDNA基因分型的研究[J].中华微生物学和免疫学杂志,2001,21(2)：234-236.
[211]Ono Y, ondo H, Sasada R, et al.The complete nucleotide sequences of the cloned hepatitis B virus DNA subtype adr and adw. Nucleic Acids Res,1983,11: 1747-1757.
[212]Seta T, Yokoouka 0, Zmazeki F, et al.Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.J Med Virol,2000;60(1):8-16.
[213]Jardi R, Buti M, Rodriguez-Frias F, et al.Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.J Virol Methods,1999:83(1-2):181-187.
[214]Whalley SA, Brown D,Teu CG, et al. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the light Cycler. J clin Microbiol,2001;39(4):1456-1459.
[215]Stuyver L, Van Geyt C, De Gendts,et al.line probe assay for monitorring durg resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol,2000;38(2):702-707.
[216]Pastinen T, Kaitio M,Lindroo S, et al.A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res,2000;10(7):1031-1042.
[217]Hei RA, De Wide GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphouylmethoxyethyl)-adenine(PMEA)on human and duck hepatitis B virus infection Antiviral Res,1993:141-153.
[218]Jutin G, Julander,Robert W, Si dwell, Johu D, Morrey. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Resarch.2002,55:27-40.
[219]郭兴伯,朱宇同,王新华等.叶下珠复方的实验和临床研究[S].加拿大国际中医药学术大会.2002：44.
[220]Chisari FV, Klopchin K, Moriyama T,et al. Molecular pathogenesis of hepatocellular carcionma in HBV transgenic mice.Cell,1989,59:1145.
[221]骆抗先.乙型肝炎的基础和临床.北京：人民卫生出版社.第一版.1997：115-131
[222]Pasquetto V, wieland S, chisari FV. Intracelluar hepatitis B virus nueleoepsids survive eytotoxie T-lymphocyte-induced apoptosis.J virol, 2000,74:9792-9796.
[223]Wang KX, Peng JI, Wang XF, et al. Detection of Tlymphocyte subsets and mIL-2R on suface of PBMC in patients with hepatitis B.world J Gastroenterol,2003,9:2017-2020.
[224]Yang PM, Du TJ, Lai MY, et al. Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of lymphocytes.AMT Gastroenterol,1998,83:948-951.
[225]Tung MC, Spengler U, Schraut W,et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol.1991,13:313-317.
[226]Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to mutiple hepatitis B virus polymerase epitopes during and acute viral hepatitis. J Exp Med.1995,181:1047-1058.
[227]骆抗生.乙型肝炎基础与临床,北京,人民卫生出版社,第2版,2001：188-189.
[228]Kozil MJ, Cytokines in viral hepatitis. Semin Liver Dis;1999,19:157-1699.
[229]Chronic hepatitis B virus infection. J Gastoenterol Hepatol.2000,15: 46-52.
[230]黄茵.慢性感染的免疫耐药形成机制.国外医学流行病学传染病学分册.2001.(2) ： 57.
[231]陈亚冈,马亦林,屠中元等.乙型慢性活动性肝炎患者外周血淋巴细胞亚群及IL-2受体表达.中华传染病杂志,1992,10(1)：48-49.
[232]Vingrhoets J, Michielsen P,Vanham G, et al.HBV-specifie lymphopro-liferative and cytokine reponses with chronic hepatitis. J Hepatol,1998, 28:8-16.
[233]万克清,阳虚,郑宣鹤.香茹多糖注射液对慢性活动性肝炎外周血T淋巴细胞亚群和IL-2受体表达作用的研究.中国免疫学杂志,1995, (5)：298.
[234]毕青,张俊福,温玉焕等.复方仙灵脾冲剂对慢性乙型肝炎Sil-2RT淋巴细胞亚群的影响.中西医结合肝病杂志,2000, (1)：14.
[235]张广业,王亚群,张玮.中医药免疫调节治疗慢性乙型病毒性肝炎研究进展.安徽中医临床杂志,2002；14(6)：518-520.
[236]黄争荣.中药复方对慢性乙型肝炎的免疫调节作用研究进展.福建中医学院学报,2003,13(1)：62-64.
[237]周春祥,徐强,曹劲松等,四逆散改善细胞免疫性肝损伤作用机理研究.中国中医基础医学杂志,2002,8(5)：47-49.
[238]Rabey AK, Mclachlan A. The biology of hepatitis B virus. Molecular biology of the hepatitis B virus.Boca Raton, FL, CRC Press;1991:1-37.
[239]Babinet C, Farza H, Morell D, et al. Specific expression of hepatitis B surface antigen(HEsAg) in transgenic mice,Science 1985,230:1160-1163.
[240]Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenice mice. Cancer Res 1990,50: 24..-3407.
[241]Chen Y, Wei H, Gao B, et al. Activation and function of hepatic NK cells in hepatitis B infection:an underinvestigated innate immmune response. J Viral Hepatitis,2005,1:34-38.
[242]U. protzer, H. Schaller. Immune Escape by Hepatitis B viruse. Virus Genes 2000,21:1/2,27-37.
[243]Guidotti L. G, Rochford R, chung I, et al. Viral clearance without Desturuction of Infected cells During Acute HBV Infection. Science 1999,284: 825-829.
[244]Penna A, Del Prete. G,Gavalli A, et al.Predominant Thepel cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute selflimited hepatitis B. Hepatology,1997,25:1022-1027.
[245]Bertoletti A, D'Elios, MM, Boni C,et al. Different cytokine Profiles of intraphaphepatic T cells in Chronic hepatitis B and hepatitis C virus infections, Gastroenterology,1997,112:193-199.
[246]Romero R, and Lavine J. E. Cytokine inhibition of the hepatitis B virus core promoter. Hepatology,1996,23:17-23.
[247]Guy B, Pascal N, Francon A, et al. Design characterization and Dreclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine,2001,19:1794.
[248]Del Giobbo,Foli A, Balarini J, et al. Immmunouiodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine(PMEA),a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res.1991,16:65-75.
[249]Cooksley H,Chokshi S, Wedemeyer H, et al.Hepatitis B virus-specific T-cell reactivity during adeforvir dipivoxil(ADV)treatment:a mulyicentre, controlled study.J Hepatol,2002,36;7.
[250]刘林华,阿德福韦酯抗乙肝病毒治疗进展.国外医学病毒学分册.2005,12(5)：154.
[251]周娟,李连闯,毕明刚等.慢性乙肝的细胞免疫病毒和中药与植物药治疗.国外医学.植物药分册,2006,21(5);202-206.
[252]顾缨.中药免疫调节剂治疗乙型病毒性肝炎的研究近况.中医药临床杂志,2005,17(3)：311-312.
[253]Bertoletti A, Maini MK. Protection or damage:a dual role for the virus-specigfic cytotoxic T lymphocyte response in hepipis B cudc infection curr Opin Immunol,2000,12:403-408.
[254]Boni C,Penna A, Ogg GS, Bertoletti A,et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy. Hepatalogy,2001,33:963-967.
[255]Fukuda R, Ishimura N, Nguyen TX, et al. The expression of and IL-2, IL-4 and interferon-gamma(INF-ganmma)mRNA/using liver different prases of acute exaceberbation if chronic hepatitis B chi clin Exp Immunol,1995,
100(3):446-451.
[256]孙剑,候金林.慢性乙型肝炎核苷类似物治疗过程中耐药性的产生及防治[J].国外医学内科分册.1998,25(10)：422.
[257]中华医学会传染病分会.肝病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2006.15-17.
[258]拉米夫定临床应用专家组.2004年拉米夫定临床应用应用专家共识.中华肝脏病杂志,2006：15-17.
[259]Locamini SA, Hepatitis B virus surface antigen and polynerase genevariant:potential virological and clinical significance[J]. Hepatology.1998,27:294.
[260]Dusheika G. Lamivudine therapy for hepatitis B infection[J]Seand J Gastroenterol,1999,230(suppl):76.
[261]刘林华,陈新月.阿德福韦酯抗乙肝病毒治疗进展[J].国外医学病毒学分册.2005,12(5)：235-237.